About SYNIMMUNE
SYNIMMUNE is a company based in Tubingen (Germany) founded in 2010 was acquired by VERAXA in December 2023. SYNIMMUNE operates in a competitive market with competitors including Jazz Pharmaceuticals, Blueprint Medicines, PureTech Health, Deciphera and Exelixis, among others.
- Headquarter Tubingen, Germany
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of SYNIMMUNE
Detailed funding history for SYNIMMUNE
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in SYNIMMUNE
SYNIMMUNE has secured backing from 1 investor. Prominent investors backing the company include VERAXA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibody therapeutics for cancer treatment are developed via microfluidic screening.
|
Locked | Locked | Locked |
Investor details for SYNIMMUNE
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SYNIMMUNE
Investment portfolio details for SYNIMMUNE
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SYNIMMUNE
Detailed financials for SYNIMMUNE
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Synimmune Comparisons
Peer comparison for SYNIMMUNE
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SYNIMMUNE
SYNIMMUNE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Blueprint Medicines, PureTech Health, Deciphera and Exelixis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Type 2 kinase inhibitors for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecule drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company focused on cancer therapeutics development.
|
Detailed competitors of SYNIMMUNE
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synimmune
Complete news archive for SYNIMMUNE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SYNIMMUNE
SYNIMMUNE was founded in 2010.
SYNIMMUNE is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
SYNIMMUNE was founded in 2010 as a spin-off from the University of Tübingens Department of Immunology. Early-stage development of mono- and bispecific antibodies targets cancer therapies, with operations based in Tübingen, Germany. Over 6.4 million in grants has been secured from the German Ministry of Education and Research. The pipeline includes two FLT3-targeted candidates: FLYSYN, a chimeric IgG1 antibody in Phase 1, and TACSYN, a bispecific antibody in Phase 2.
SYNIMMUNE's top competitors include Jazz Pharmaceuticals, Juno Therapeutics and Deciphera.
SYNIMMUNE has 1 investor. Key investors include VERAXA.